GeneHealth - Your precision medicine

Biliary Atresia

Disease Details

Family Health Simplified

Buy Membership

Description: Biliary atresia is a life-threatening condition in infants where the bile ducts inside or outside the liver do not develop normally, leading to bile buildup, liver damage, and cirrhosis.
Type: Biliary atresia is a type of congenital liver disease that affects the bile ducts. Its exact cause is not well understood, and it is typically not considered to be inherited in a straightforward genetic manner. Most cases are sporadic, meaning they occur by chance and are not passed from parent to child. However, in some rare instances, genetic or environmental factors might contribute to the condition.
Signs And Symptoms: Initially, the symptoms of biliary atresia are indistinguishable from those of neonatal jaundice, a usually harmless condition commonly seen in infants. However, infants with biliary atresia develop progressive conjugated jaundice, pale white stools, and dark urine. Some infants fail to thrive as there will be a degree of fat and fat-soluble vitamin malabsorption (e.g. Vitamin K). This may cause a bleeding tendency. Eventually, and usually after 2 months, cirrhosis with portal hypertension will develop. If left untreated, biliary atresia can lead to liver failure. Unlike other forms of jaundice, however, biliary-atresia-related cholestasis mostly does not result in kernicterus, a form of brain damage resulting from liver dysfunction. This is because in biliary atresia, the liver, although diseased, is still able to conjugate bilirubin, and conjugated bilirubin is unable to cross the blood–brain barrier.
Prognosis: Biliary atresia is a serious liver condition affecting newborns, leading to bile duct obstruction. The prognosis varies:

1. **Early Diagnosis and Treatment**: If diagnosed and treated early with a Kasai procedure (hepatoportoenterostomy), the outcomes improve significantly. About 60-80% of infants achieve bile flow; however, effectiveness decreases if performed after 60 days of age.

2. **Liver Transplantation**: Many children eventually require liver transplantation. While the procedure carries risks, it generally offers good long-term survival rates.

3. **Long-term Outlook**: Without surgery, the condition leads to liver failure. With successful interventions, many children lead relatively normal lives, though ongoing medical supervision is necessary.

Overall, timely medical intervention is crucial for a better prognosis in biliary atresia.
Onset: Biliary atresia typically presents itself within the first few weeks to months of life. Newborns with this condition usually appear healthy at birth but then develop symptoms such as jaundice, dark urine, pale stools, and poor weight gain. The onset of noticeable symptoms generally occurs between 2 to 8 weeks after birth. If untreated, biliary atresia can lead to liver damage and cirrhosis.
Prevalence: Biliary atresia is a rare pediatric liver disease. The prevalence varies globally but is generally estimated to occur in about 1 in 10,000 to 20,000 live births.
Epidemiology: Biliary atresia seems to affect females slightly more often than males, and Asians and African Americans more often than Caucasians. It is common for only one child in a pair of twins or within the same family to have the condition. There seems to be no link to medications or immunizations given immediately before or during pregnancy. Diabetes during pregnancy particularly during the first trimester seems to predispose to a number of distinct congenital abnormalities in the infant such as sacral agenesis, transposition of the great vessels and the syndromic form of biliary atresia.
Intractability: Biliary atresia is considered intractable if not treated early. It often requires surgical intervention, such as the Kasai procedure, and may ultimately necessitate a liver transplant. Early diagnosis and treatment are crucial for improved outcomes.
Disease Severity: Biliary atresia is a severe liver condition that affects infants and can lead to life-threatening complications if not treated. The severity depends on how quickly it is diagnosed and treated. Without timely surgical intervention, such as the Kasai procedure or liver transplantation, the disease can progress to liver failure.
Healthcare Professionals: Disease Ontology ID - DOID:13608
Pathophysiology: There are three main types of extra-hepatic biliary atresia:
Type I: Atresia is restricted to the common bile duct.
Type II: Atresia of the common hepatic duct.
Type III: Atresia involves the most proximal part of the bile ducts (>95% of all cases).In approximately 10% of cases, other anomalies may be associated with biliary atresia. The most common of these syndromic forms is BASM and might include heart lesions, polysplenia, situs inversus, absent venae cavae, and a preduodenal portal vein. Progressive cirrhosis is associated with signs and symptoms of portal hypertension, such as esophagogastric varix bleeding, hypersplenism, hepatorenal syndrome, and hepatopulmonary syndrome.In an Egyptian study, abnormally high levels of aflatoxin B1 and to a lesser extent aflatoxin B2 was found in liver tissue and blood of all neonates with biliary atresia. Aflatoxins may cause extensive damage to the hepatocytes leading to hepatitis and damage to bile ducts causing inflammation, adhesions and final obstruction of bile ducts. The affected neonates have a genetic detoxification defect that does not allow them to detoxify these aflatoxins timely or effectively. The babies have homozygous deficiency of glutathione S transferase (GST) M1. The aflatoxin damaged liver cells and bile duct cells are removed by neutrophil elastase and by involvement of immune system mediators such as CCL-2 or MCP-1, tumor necrosis factor (TNF), interleukin-6 (IL-6), TGF-beta, endothelin (ET), and nitric oxide (NO). Among these, TGF-beta is the most important pro-fibrogenic cytokine that can be seen in progressive cirrhosis.The cascade of immune involvement to remove damaged hepatocytes and cholangiocytes ushers regeneration. Yet in infants with biliary atresia regeneration is defective, and results in cirrhosis, as these infants have disrupted p53 and disrupted GSTPi. p53 and GSTPi are responsible for DNA fidelity at regeneration. Hence, these infants get accelerated cirrhosis and march to portal hypertension.
Carrier Status: Biliary atresia is not typically associated with a carrier status as it is not a genetic condition inherited in a simple Mendelian manner. It is a rare disease of the liver and bile ducts that occurs in infants, where the bile ducts become blocked or absent. The exact cause of biliary atresia is unknown, but it is believed to result from a combination of genetic and environmental factors.
Mechanism: Biliary atresia is a pediatric liver disease characterized by the obstruction or absence of bile ducts. It results in bile flow impairment from the liver to the intestine, causing liver damage and jaundice.

**Mechanism:**
In biliary atresia, inflammatory and fibrotic processes lead to the destruction and obliteration of bile ducts. This blockage prevents bile from being released into the intestine, causing bile to accumulate in the liver. The buildup of bile can damage liver cells (hepatocytes), leading to fibrosis, cirrhosis, and liver failure if left untreated.

**Molecular Mechanisms:**
The exact molecular mechanisms underlying biliary atresia are not completely understood, but they involve several potential factors:

1. **Genetic Factors:** Certain genetic mutations and polymorphisms may predispose individuals to biliary atresia. Specific genes involved in bile duct morphogenesis and immune regulation have been implicated.

2. **Immune-Mediated Injury:** An immune response against bile duct cells may play a role. This involves the activation of immune cells like T lymphocytes and macrophages, which release cytokines and other inflammatory mediators that damage bile ducts.

3. **Viral Infections:** Some studies suggest that perinatal viral infections (e.g., reovirus, rotavirus) might trigger an aberrant immune response, leading to bile duct injury.

4. **Developmental Abnormalities:** Defects during embryonic development of the biliary system could contribute to the formation of atretic bile ducts.

5. **Inflammatory Pathways:** Activation of inflammatory pathways, such as those involving NF-κB and other cytokine signaling cascades, have been observed in biliary atresia, contributing to cholangiocyte (bile duct cell) proliferation, fibrosis, and bile duct obliteration.

6. **Fibrogenesis:** Inflammatory damage leads to activation of hepatic stellate cells, promoting the deposition of extracellular matrix proteins and fibrogenesis in the liver.

Research is ongoing to fully elucidate these mechanisms and develop targeted therapies for biliary atresia. Early surgical intervention, such as the Kasai procedure, is currently the primary treatment to restore bile flow and prevent liver damage.
Treatment: Most (>95%) infants with biliary atresia will undergo an operation designed to retain and salvage the native liver, restore bile flow, and reduce the level of jaundice. This is known as the Kasai procedure (after Morio Kasai, the Japanese surgeon who first developed the technique) or hepatoportoenterostomy. Although the procedure is not thought of as curative, it may relieve jaundice and stop liver fibrosis, allowing normal growth and development. Published series from Japan, North America, and the UK show that bilirubin levels will fall to normal values in about 50-55% of infants, allowing 40-50% to retain their own liver to reach the age of 5 and 10 years (and beyond). Liver transplantation is an option for those children whose liver function and symptoms fail to respond to a Kasai operation.Recent large-scale studies by Davenport et al. (Annals of Surgery, 2008) show that the age of the patient is not an absolute clinical factor affecting prognosis. The influence of age differs according to the disease etiology—i.e., whether biliary atresia is isolated, cystic (CBA), or accompanied by splenic malformation (BASM).It is widely accepted that corticosteroid treatment after a Kasai operation, with or without choleretics and antibiotics, has a beneficial effect on postoperative bile flow and can clear jaundice, but the dosing and duration of the ideal steroid protocol are controversial. Furthermore, it has been observed in many retrospective longitudinal studies that corticosteroid treatment does not seem to prolong survival of the native liver or transplant-free survival.
Compassionate Use Treatment: For biliary atresia, compassionate use treatments and off-label or experimental options might include the following:

1. **Liver Transplantation**: While liver transplantation is a standard treatment, it can be sought under compassionate use circumstances when other treatments fail or are not available.

2. **Ursodeoxycholic Acid (UDCA)**: Although not a cure, UDCA is sometimes used off-label to improve bile flow and liver function.

3. **High-dose Steroids**: Occasionally used off-label post-Kasai portoenterostomy to reduce inflammation and fibrosis, although the efficacy remains controversial and is not a standard practice.

4. **Experimental Therapies**: These could include novel drugs or biological agents under clinical trials aimed at improving bile flow or liver regeneration. Participation in such trials often falls under compassionate use protocols when standard treatments are exhausted.

5. **Gene Therapy and Stem Cell Transplants**: Areas of ongoing research which, though not yet standardized, might be considered in specific contexts under experimental treatment frameworks.

Always consult with healthcare providers specializing in pediatric hepatology for the most current and applicable treatment options.
Lifestyle Recommendations: For individuals with biliary atresia, lifestyle recommendations are:

1. **Nutritional Support**: Ensure a well-balanced diet with adequate calories and nutrients, often requiring high-calorie formulas or supplements, especially if the patient has poor weight gain.

2. **Vitamin Supplementation**: Supplement fat-soluble vitamins (A, D, E, K) due to impaired bile flow affecting their absorption.

3. **Monitoring for Complications**: Regularly monitor liver function and watch for signs of complications such as portal hypertension, cholangitis, or liver failure.

4. **Activity**: Maintain age-appropriate physical activity levels unless otherwise advised by a healthcare provider, promoting overall health and well-being.

5. **Medical Follow-Up**: Adhere to regular follow-up appointments with healthcare providers, including pediatric hepatologists and dietitians, to monitor the condition and adjust treatment as necessary.

6. **Infection Prevention**: Practice good hygiene and possibly receive vaccinations for hepatitis and other infectious diseases, as recommended by a healthcare provider.

7. **Social Support**: Engage in support networks, either through patient groups or counseling, to manage the emotional and psychological impact of living with a chronic illness.
Medication: There are currently no medications that can cure biliary atresia. Treatment typically involves surgical intervention, specifically the Kasai procedure, which aims to restore bile flow from the liver to the intestines. In cases where the Kasai procedure is not successful or the disease progresses, liver transplantation may be necessary. Medications may be used to manage symptoms and complications, such as antibiotics for infections, ursodeoxycholic acid to improve bile flow, and vitamin supplements to address deficiencies.
Repurposable Drugs: Biliary atresia is a rare liver disease in newborns where the bile ducts become blocked or absent. This condition leads to liver damage and requires early intervention. While there are no widely accepted repurposable drugs specifically for biliary atresia, treatment primarily involves surgical intervention, particularly the Kasai procedure. Post-surgery, medications may be used to manage symptoms and support liver function, but they are not curative. Research is ongoing to find potential medical therapies, including repurposing existing drugs.
Metabolites: Biliary atresia is a rare liver disease in newborns where the bile ducts become blocked or absent. This blockage leads to the build-up of bile in the liver, causing liver damage. Key metabolites affected in biliary atresia include:

1. **Bilirubin:** Elevated levels of both conjugated (direct) and unconjugated (indirect) bilirubin due to the impaired excretion of bile.
2. **Bile Acids:** Increased serum bile acids due to the obstruction of bile flow.
3. **Liver Enzymes:** Elevated levels of liver enzymes such as alanine aminotransferase (ALT), aspartate aminotransferase (AST), and gamma-glutamyl transferase (GGT) indicating liver damage.
4. **Alkaline Phosphatase (ALP):** Often increased, reflecting cholestasis (reduced bile flow).

Prompt diagnosis and surgical treatment, such as the Kasai procedure, are crucial to manage the condition and prevent severe liver damage.
Nutraceuticals: Biliary atresia is a serious condition in infants where the bile ducts become blocked, leading to liver damage. Nutraceuticals, such as certain vitamins and minerals, may support general liver health but should not be considered a treatment for biliary atresia. Management typically involves surgical intervention, such as the Kasai procedure, and in severe cases, a liver transplant may be necessary. Always consult a healthcare provider for appropriate diagnosis and treatment options.
Peptides: Biliary atresia is a rare liver disease occurring in infants, where the bile ducts inside or outside the liver do not develop properly, leading to bile buildup, liver damage, and eventually liver failure. It is typically treated through surgery (Kasai procedure) and possibly liver transplantation. While various treatments and interventions may be researched, there is no established treatment involving peptides or nanotechnology specifically for biliary atresia as of the latest updates.